See more : Eminent Gold Corp. (EMNT.V) Income Statement Analysis – Financial Results
Complete financial analysis of Bliss GVS Pharma Limited (BLISSGVS.BO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bliss GVS Pharma Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Youji Corporation (2152.T) Income Statement Analysis – Financial Results
- Accel Entertainment, Inc. (TPGH-UN) Income Statement Analysis – Financial Results
- Victor Mining Industry Group Inc. (VMTG) Income Statement Analysis – Financial Results
- HTC Corporation (HTCKF) Income Statement Analysis – Financial Results
- EFOR CAY SANAYI (EFORC.IS) Income Statement Analysis – Financial Results
Bliss GVS Pharma Limited (BLISSGVS.BO)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.blissgvs.com
About Bliss GVS Pharma Limited
Bliss GVS Pharma Limited develops, manufactures, and markets pharmaceutical formulations in India. It offers pharma products, including capsules, creams/gels/ointments, dry powder for injections and oral suspensions, effervescent tablets, eye/ear drops, injections, liquid preparations, lotions, lozenges, nasal solutions, oral solids, parenterals, pessaries, sachets, soft gelatin capsules, suppositories, suspensions, syrups, tablets, topical preparations, and transdermal patches. The company provides other healthcare products, such as balms, creams, lotions, lozenges, nasal inhalers, over the counter products, petroleum jellies, powders, roll-ons, shampoos, soaps, solutions, sprays, syrups, and vaginal washes. In addition, it offers therapeutic products consisting of anti-bacterial, anti-dandruff shampoo, amino acid preparation, iron tonic, antitussive, appetite stimulant, anti-allergic, body supplement, anti-biotic, anti-diabetic, anti-diarrheal, anti-emetic, anti-fungal, anti-haemorrhoidal, anti-helmintic, anti-infective, anti-inflammatory, anti-malarial, anti-microbial, anti-migraine, anti-oxidant, anti-protozoal, ear wax solvent, anti-pyretic, anti-septic, anti-spasmodic, anti-ulcer, and anti-ulcerant; and analgesic, oral rehydration, antacid, anxiolytic, appetizer, cough syrup, erectile dysfunction, haematinic, hand sanitizer, health supplement, insecticide, laryngitis, pharyngitis, laxative, lubricant, mosquito repellant, nasal decongestant, nutritional supplement, moisturizer, prickly heat powder, skin lightening lotion, vaginal contraceptive, vaginal hygiene, and vitamin supplements, as well as soaps. The company exports its products. Bliss GVS Pharma Limited was incorporated in 1984 and is based in Mumbai, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.66B | 7.47B | 7.38B | 5.69B | 6.82B | 8.86B | 3.64B | 3.77B | 5.47B | 4.07B | 3.45B | 3.97B | 2.67B | 2.19B | 1.69B | 1.33B | 1.02B | 623.39M |
| Cost of Revenue | 5.16B | 4.01B | 3.91B | 3.30B | 4.40B | 6.12B | 1.94B | 1.91B | 2.58B | 1.78B | 1.71B | 2.03B | 1.57B | 1.27B | 905.73M | 698.41M | 445.94M | 356.59M |
| Gross Profit | 2.49B | 3.46B | 3.47B | 2.39B | 2.42B | 2.74B | 1.70B | 1.86B | 2.89B | 2.30B | 1.74B | 1.93B | 1.10B | 914.44M | 783.03M | 631.15M | 578.02M | 266.81M |
| Gross Profit Ratio | 32.57% | 46.31% | 47.02% | 42.02% | 35.48% | 30.93% | 46.61% | 49.36% | 52.76% | 56.39% | 50.49% | 48.74% | 41.04% | 41.79% | 46.37% | 47.47% | 56.45% | 42.80% |
| Research & Development | 152.30M | 217.89M | 220.04M | 104.01M | 76.89M | 142.55M | 26.07M | 142.40M | 32.09M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 84.08M | 72.77M | 85.99M | 69.70M | 60.44M | 72.19M | 43.28M | 70.49M | 574.39M | 410.38M | 47.36M | 45.64M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 346.81M | 421.65M | 451.78M | 209.51M | 211.37M | 204.69M | 153.24M | 189.79M | 318.51M | 353.49M | 351.17M | 402.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 430.88M | 494.42M | 537.77M | 279.21M | 271.81M | 276.88M | 196.52M | 260.28M | 892.90M | 763.87M | 828.43M | 658.94M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | -6.95M | 21.48M | 24.00M | 27.60M | 14.63M | 5.71M | 88.83M | 24.33M | 26.77M | 26.77M | 27.84M | 2.90M | 515.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.42B | 2.45B | 2.29B | 1.48B | 1.28B | 1.14B | 821.29M | 889.05M | 1.46B | 1.30B | 1.13B | 881.77M | 428.15M | 284.14M | 305.04M | 206.00M | 211.86M | 201.51M |
| Cost & Expenses | 6.43B | 6.47B | 6.20B | 4.78B | 5.68B | 7.27B | 2.76B | 2.80B | 4.04B | 3.07B | 2.84B | 2.91B | 2.00B | 284.14M | 1.21B | 904.40M | 657.81M | 558.09M |
| Interest Income | 117.90M | 75.04M | 88.18M | 95.79M | 66.79M | 68.14M | 46.78M | 61.73M | 69.01M | 55.23M | 40.55M | 38.84M | 22.31M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 69.12M | 32.44M | 29.30M | 60.30M | 68.98M | 41.40M | 81.95M | 118.87M | 163.01M | 153.90M | 168.36M | 97.18M | 40.31M | 21.47M | 20.44M | 22.62M | 13.83M | 6.66M |
| Depreciation & Amortization | 263.78M | 186.72M | 173.29M | 172.28M | 125.88M | 89.44M | 90.71M | 106.90M | 142.51M | 122.87M | 112.07M | 61.24M | 36.46M | 54.70M | 54.01M | 35.91M | 29.27M | 29.17M |
| EBITDA | 1.49B | 1.35B | 762.37M | 1.27B | 1.49B | 1.95B | 816.67M | 1.12B | 1.80B | 1.24B | 986.02M | 1.10B | 704.30M | -284.14M | 536.91M | 461.07M | 395.42M | 94.47M |
| EBITDA Ratio | 19.43% | 17.35% | 22.35% | 22.68% | 24.06% | 23.23% | 34.91% | 33.25% | 32.76% | 32.26% | 28.61% | 27.86% | 26.37% | -12.98% | 31.50% | 34.68% | 38.62% | 15.15% |
| Operating Income | 1.23B | 978.61M | 950.22M | 830.25M | 1.06B | 1.42B | 812.35M | 675.48M | 1.32B | 1.19B | 873.95M | 1.04B | 667.84M | -338.83M | 477.99M | 425.15M | 366.15M | 65.30M |
| Operating Income Ratio | 16.07% | 13.09% | 12.88% | 14.60% | 15.51% | 15.97% | 22.33% | 17.91% | 24.22% | 29.24% | 25.36% | 26.31% | 25.01% | -15.48% | 28.30% | 31.98% | 35.76% | 10.47% |
| Total Other Income/Expenses | -62.28M | 53.38M | -408.57M | -528.13M | -449.48M | -246.75M | -234.72M | -93.89M | -576.98M | -230.45M | -148.62M | 51.22M | 126.35M | -5.33M | -20.44M | -22.62M | -13.83M | -6.66M |
| Income Before Tax | 1.17B | 1.06B | 541.65M | 1.04B | 1.29B | 1.82B | 639.94M | 879.05M | 1.48B | 960.19M | 705.58M | 1.09B | 794.19M | 529.81M | 457.55M | 402.54M | 352.32M | 58.64M |
| Income Before Tax Ratio | 15.26% | 14.19% | 7.34% | 18.31% | 18.91% | 20.52% | 17.59% | 23.30% | 27.10% | 23.58% | 20.47% | 27.60% | 29.74% | 24.21% | 27.09% | 30.28% | 34.41% | 9.41% |
| Income Tax Expense | 352.94M | 293.37M | 310.39M | 301.55M | 337.12M | 552.53M | 322.69M | 363.80M | 480.49M | 346.26M | 295.27M | 498.98M | 268.84M | 123.51M | 40.34M | 28.02M | 14.97M | 20.23M |
| Net Income | 754.54M | 708.59M | 150.40M | 684.91M | 972.65M | 1.24B | 587.85M | 820.47M | 824.83M | 599.10M | 409.92M | 577.20M | 525.36M | 406.30M | 417.22M | 374.51M | 337.35M | 38.41M |
| Net Income Ratio | 9.85% | 9.48% | 2.04% | 12.04% | 14.26% | 13.96% | 16.16% | 21.75% | 15.08% | 14.71% | 11.89% | 14.55% | 19.67% | 18.57% | 24.71% | 28.17% | 32.95% | 6.16% |
| EPS | 7.23 | 6.83 | 1.46 | 6.64 | 9.43 | 11.99 | 5.70 | 7.95 | 8.00 | 5.81 | 3.97 | 5.60 | 5.09 | 3.94 | 4.04 | 3.63 | 2.04 | 6.53 |
| EPS Diluted | 7.11 | 6.72 | 1.43 | 6.49 | 9.43 | 11.99 | 5.70 | 7.95 | 8.00 | 5.81 | 3.97 | 5.60 | 5.09 | 3.94 | 4.04 | 3.63 | 2.04 | 6.53 |
| Weighted Avg Shares Out | 104.36M | 103.81M | 103.34M | 103.15M | 103.15M | 103.15M | 103.15M | 103.15M | 103.15M | 103.15M | 103.15M | 103.15M | 103.15M | 103.15M | 103.15M | 103.15M | 165.03M | 5.88M |
| Weighted Avg Shares Out (Dil) | 106.07M | 105.48M | 105.20M | 105.48M | 103.15M | 103.15M | 103.15M | 103.15M | 103.15M | 103.15M | 103.15M | 103.15M | 103.15M | 103.15M | 103.15M | 103.15M | 165.03M | 5.88M |
Source: https://incomestatements.info
Category: Stock Reports